New radiotherapy approaches in locally advanced non-small cell lung cancer

作者：Christodoulou Marianna; Bayman Neil; McCloskey Paula; Rowbottom Carl; Faivre Finn Corinne^*

来源：European Journal of Cancer, 2014, 50(3): 525-534.

DOI：10.1016/j.ejca.2013.11.027

• Lung cancer
• Non-small cell lung cancer
• Radiotherapy
• Dose escalation
• Altered fractionation
• Intensity modulated radiotherapy
• Image-guided radiation therapy
• Proton beam therapy
• Personalised radiotherapy

Radiotherapy plays a major role in the treatment of patients with locally advanced non-small cell lung cancer (NSCLC), particularly since most patients are not suitable for surgery due to the extent of their disease, advanced age and multiple co-morbidities. Despite advances in local and systemic therapies local control and survival remain poor and there is a sense that a therapeutic plateau has been reached with conventional approaches. Strategies for the intensification of radiotherapy such as dose escalation have shown encouraging results in phase I-II trials, but the outcome of the phase III Radiation Therapy Oncology Group 0617 trial was surprisingly disappointing. Hyperfractionated and/or accelerated fractionating schedules have demonstrated superior survival compared to conventional fractionation at the expense of greater oesophageal toxicity. Modern radiotherapy techniques such as the integration of 4-dimensional computed tomography for planning, intensity modulated radiotherapy and image-guided radiotherapy have substantially enhanced the accuracy of the radiotherapy delivery through improved target conformality and incorporation of tumour respiratory motion. A number of studies are evaluating personalised radiation treatment including the concept of isotoxic radiotherapy and the boosting of the primary tumour based on functional imaging. Proton beam therapy is currently under investigation in locally advanced NSCLC. These approaches, either alone or in combination could potentially allow for further dose escalation and improvement of the therapeutic ratio and survival for patients with NSCLC.

• 出版日期2014-2